GC
INMB icon

GatePass Capital’s INmune Bio INMB Stock Holding History

GatePass Capital’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-235,000
Closed -$1.84M – 128
2025
Q1 		$1.84M Buy
235,000
+80,000
+52% +$635K 1.37% 15
2024
Q4 		$724K Buy
+155,000
New +$808K 0.79% 31

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

GatePass Capital's INMB Position: Q2 2025 in Review

GatePass Capital sold out of INmune Bio (INMB) in Q2 2025, closing a stake of 235,000 shares — an estimated $1.84M sold.

GatePass Capital first reported a position in INMB in Q4 2024 and held it in 2 quarters. The position peaked at $1.84M in Q1 2025. 79 funds tracked by Wall St. Rank hold INMB as of Q2 2025.

  • GatePass Capital reported no remaining INmune Bio position as of Q2 2025 after selling out during the quarter.
  • GatePass Capital sold 235,000 INmune Bio shares in Q2 2025, an estimated $1.84M.
  • GatePass Capital first reported a position in INmune Bio in Q4 2024 and held it in 2 quarters.
  • GatePass Capital's INmune Bio position peaked at $1.84M in Q1 2025.
  • 79 funds tracked by Wall St. Rank held INmune Bio as of Q2 2025.

Based on GatePass Capital's 13F filing for Q2 2025, filed 22 Sep 2025.